METHOD OF PREDICTING THE STATUS OF EPIDERMAL GROWTH FACTOR RECEPTOR HER2/NEU IN METASTATIC AXILLARY LYMPH NODES IN PATIENTS WITH BREAST CANCER Russian patent published in 2023 - IPC A61B6/03 G01T1/164 

FIELD: medicine; oncology.

SUBSTANCE: invention can be used to predict the status of the HER2/neu receptor in metastatic axillary lymph nodes in patients with breast cancer. At the stage of clinical examination, prior to the start of systemic treatment, patients with breast cancer with metastases in the axillary lymph nodes are administered the radionuclide pharmaceutical preparation [^99mTc]Tc-ADAPT6 at a dose of 500 μg. After 2 hours, single-photon emission computed tomography (SPECT/CT) of the chest organs is performed and the accumulation of radiopharmaceuticals in the metastatic axillary lymph node X is assessed. The value of the regression equation Y is calculated using the formula Y = -6.827 + 1.751*X, where -6.827 is the value of the regression coefficient of the free term; X is an indicator of the quantitative accumulation of radiopharmaceuticals in the metastatic axillary lymph node; 1.751 is the value of the regression coefficient of this feature. The probability P of assessing the status of the HER2/neu receptor in the metastatic axillary lymph node is determined by the formula P = e^Y/(1 + e^Y). At P≥ 50% high probability of HER2-positive tissue status of the primary tumor node is predicted, and at P<50% low probability of HER2-positive tissue status of the primary tumor node is predicted.

EFFECT: method provides improved accuracy of HER2/neu receptor status prediction in metastatic axillary lymph nodes in patients with breast cancer.

1 cl, 2 dwg, 2 ex